Latigo Biotherapeutics priced an upsized IPO to raise $345.6 million for a non-opioid pain pipeline targeting Nav1.8. The offering reflects ongoing investor appetite for mechanism-led late-stage translational concepts and suggests continuing capacity for bigger-than-expected biotech floats in 2026. Separately, Blossomhill Therapeutics priced a $150 million IPO to fund next-generation macrocyclic inhibitors, including programs aimed at EGFR-mutant non-small-cell lung cancer. Both deals add to a busy issuance window as companies seek funding to advance early pipeline programs toward clinical proof.